These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12686820)

  • 21. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent progress in hormonal therapy for advanced prostate cancer.
    Daskivich TJ; Oh WK
    Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
    Jani AB; Kao J; Hellman S
    Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.
    Yaffe K; Vittinghoff E; Ensrud KE; Johnson KC; Diem S; Hanes V; Grady D
    Arch Neurol; 2006 Jul; 63(7):945-50. PubMed ID: 16831962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
    Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and management of gynecomastia in men treated for prostate cancer.
    Dobs A; Darkes MJ
    J Urol; 2005 Nov; 174(5):1737-42. PubMed ID: 16217274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
    Taxel P; Luthra P; Fall PM; Dauser D
    Aging Male; 2008 Jun; 11(2):71-5. PubMed ID: 18570058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in C-reactive protein levels induced by different application forms of estrogen replacement therapy].
    Fait T; Vrablík M; Kostírová M; Trnková B
    Cas Lek Cesk; 2006; 145(7):571-4; discussion 574. PubMed ID: 16921788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two routes of hormonal replacement therapy in symptomatic menopausal women after kidney transplantation.
    Pietrzak B; Wielgos M; Kaminski P; Bobrowska K
    Neuro Endocrinol Lett; 2006 Jun; 27(3):387-91. PubMed ID: 16816826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study.
    Fait T; Vrablik M; Zizka Z; Kostirova M
    Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogens in the treatment of prostate cancer.
    Cox RL; Crawford ED
    J Urol; 1995 Dec; 154(6):1991-8. PubMed ID: 7500443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.